Molecular characterization of deletional forms of beta-thalassemia in Taiwan

CMUR > China Medical University Hospital > Jurnal articles > Item 310903500/30351

Please use this identifier to cite or link to this item: http://ir.cmu.edu.tw/ir/handle/310903500/30351

Title:	Molecular characterization of deletional forms of beta-thalassemia in Taiwan
Authors:	Peng, CT;Liu, SC;Chiou, SS;Kuo, PL;Shih, MC;Chang, JY;Chang, JG
Contributors:	附設醫院檢驗醫學部;China Med Coll Hosp, Dept Lab Med, Taichung, Taiwan;China Med Coll Hosp, Dept Pediat, Taichung, Taiwan;Kaohsiung Med Univ, Dept Pediat, Kaohsiung, Taiwan;Natl Cheng Kung Univ, Sch Med, Dept Obstet & Gynecol, Tainan 70101, Taiwan
Date:	2003
Issue Date:	2010-09-24 14:53:48 (UTC+8)
Publisher:	SPRINGER-VERLAG
Abstract:	Background: It was reported that multidrug resistance gene 1 (MDR1) encoding human P-glycoprotein (Pgp) may play an important role in multidrug resistance of lung cancer. Therefore, before initiating chemotherapy, it is important to accurately determine the presence of Pgp in lung cancer, to achieve a satisfactory chemotherapy response. Objectives: The aim of this study was to compare immunohistochemical analyses of Pgp expression and response to paclitaxel in non-small-cell lung cancer (NSCLC). Methods: Before chemotherapy with paclitaxel, 50 patients with stage IIIb or IV NSCLC were enrolled in this study. Immunohistochemical analyses were performed on multiple nonconsecutive sections of the biopsy specimens to determine Pgp expression. Chemotherapy response was evaluated in the 3rd month after completion of treatment by clinical and radiological methods. Results: All of the 28 (100%) cases with good response had negative Pgp expression and 15 of the 22 (68%) cases with poor response had positive Pgp expression (p < 0.05). No significant differences were found for other prognostic factors (age, sex, body weight loss, performance status, tumor cell type, and tumor stage) between good response and poor response groups. Conclusions: Although Pgp expression in NSCLC does not fully predict chemotherapy response to paclitaxel-based therapy, detection of Pgp expression will aid in planning paclitaxel-based therapy for patients with advanced NSCLC. Further studies with a larger number of patients and a longer time of follow-up are necessary to confirm our findings. Copyright (C) 2003 S. Karger AG, Basel.
Relation:	ANNALS OF HEMATOLOGY 82(1):33-36
Appears in Collections:	[China Medical University Hospital] Jurnal articles

Files in This Item:

There are no files associated with this item.

Loading...